The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global cell-free protein expression market size reached US$ 227.7 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 362.34 Million by 2027, exhibiting a growth rate (CAGR) of 7.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Cell-free protein expression (CFPE) refers to the production of desired recombinant proteins in solution using biomolecular translation machinery extracted from cells. It can be carried out using different cell lysates, such as E. coli, rabbit reticulocytes, wheat germ, insect cells, and mammalian cell-free protein expression systems. They are widely used in enzyme engineering, protein labeling, protein purification, protein-protein interaction, and high throughput production of mutants. CFPE is also used for analyzing components needed for protein stability, degradation, and folding. As compared to cell-based protein expression, cell-free protein expression is time efficient and convenient, allows the incorporation of non-natural amino acids, and provides enhanced stability and specificity.
The rapid advancement in biological sciences is one of the key factors driving the market growth. Cell-free protein expression is extensively used in the expansion of genetic code, assembly of viruses, and the synthesis of recombinant proteins for various biomolecular processes. Furthermore, the increasing technique utilization in the pharmaceutical industry for developing protein-based therapeutics, such as antibodies, antimicrobials, and cytokines, for treating cancer and infectious diseases is acting as another growth-inducing factor. Additionally, the integration of machine learning (ML) algorithms to improve protein production yield by optimizing the system for efficient prototyping and high-throughput experimentation is providing an impetus to market growth. Moreover, the introduction of novel processes to produce complex prokaryotic and eukaryotic proteins using a continuous-exchange cell-free (CECF) protein synthesis system is creating a positive outlook for the market. Other factors, including the widespread adoption of cell-free methods for biomanufacturing and prototyping, extensive research and development (R&D) activities in proteomics and genomics, and the rising adoption in the healthcare industry for diagnostic applications, such as pathogen sensing, inflammatory response, and personalized medicine, are supporting drive the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cell-free protein expression market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, method, application and end user.
Breakup by Product:
Breakup by Method:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bioneer Corporation, biotechrabbit GmbH, Cambridge Isotope Laboratories Inc. (Otsuka Pharmaceutical Co. Ltd.), CellFree Sciences Co. Ltd., Cube Biotech GmbH, GeneCopoeia Inc., Jena Bioscience GmbH, Merck KGaA, New England Biolabs, Promega Corporation, Takara Bio Inc. and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Method, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Bioneer Corporation, biotechrabbit GmbH, Cambridge Isotope Laboratories Inc. (Otsuka Pharmaceutical Co. Ltd.), CellFree Sciences Co. Ltd., Cube Biotech GmbH, GeneCopoeia Inc., Jena Bioscience GmbH, Merck KGaA, New England Biolabs, Promega Corporation, Takara Bio Inc. and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Vaccines, Interferons Alpha and Beta, Interleukins), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Others), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at